SignalXSignalX

LIVN LivaNova PLC

FY2025 10-K
Filed: Feb 25, 2026
Health Care
Electromedical & Electrotherapeutic ApparatusSEC EDGAR
LivaNova PLC Overview

LivaNova PLC (LIVN) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model: Medical technology company with Cardiopulmonary and Neuromodulation segments driving revenue
  • • New product emphasis: aura6000 System for treating Obstructive Sleep Apnea, increasing Neuromodulation R&D expense by $11.2M
+3 more insights

Management Discussion & Analysis

  • • Revenue and YoY change not disclosed explicitly in provided text
  • • No profitability or margin % figures available in text
+3 more insights

Risk Factors

  • • Regulatory risk from 3T Heater-Cooler device litigation provision reducing cash outflows by $71.3M in 2025
  • • Geopolitical risk from exposure to hospital and healthcare sectors across multiple countries affecting trade receivables concentration
+3 more insights

Financial Summary
XBRL

Revenue

$1.4B

Net Income

-$242M

Gross Margin

67.7%

Operating Margin

14.4%

Net Margin

-17.5%

ROE

-20.2%

Total Assets

$2.6B

EPS (Diluted)

$-4.45

Operating Cash Flow

$254M

Source: XBRL data from LivaNova PLC FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on LivaNova PLC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available